<DOC>
	<DOC>NCT02902809</DOC>
	<brief_summary>A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tralokinumab in Japanese Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid plus Long-Acting β2-Agonist</brief_summary>
	<brief_title>A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma</brief_title>
	<detailed_description>This is a 52-week, open-label, multi-centre study designed to evaluate the safety of tralokinumab in a fixed 300 mg dose every 2 weeks, administered subcutaneously in adults and adolescents with indequately controlled asthma on medium to high dose inhaled corticosteroid plus long acting β-2 antagonist. Approximately 26 Japanese subjects will be recruited to receive 22 completed.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Age 12 75 yrs 2. Documented physiciandiagnosed asthma 3. Documented treatment with inhaled corticosteroid (ICS) at a total daily dose corresponding to ≥500 µg fluticasone propionate dry powder formulation equivalents and a longacting beta2 agonist (LABA) 4. Prebronchodilator (BD) forced expiratory volume at one second (FEV1) value of ≥40% of their Predicted Normal Value (PNV) 5. Asthma Control Questionnaire6 (ACQ6) score ≥1.5 1. Pulmonary disease other than asthma 2. History of anaphylaxis following any biologic therapy 3. Hepatitis B, C or HIV 4. Pregnant of breastfeeding 5. History or cancer 6. Current tobacco smoking or a history or tobacco smoking for ≥10 packyears 7. Previous receipt of tralokinumab</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>open-label study</keyword>
	<keyword>tralokinumab</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>inadequately controlled asthma</keyword>
	<keyword>asthma</keyword>
	<keyword>medium to high-dose of inhaled corticosteroid</keyword>
	<keyword>long-acting β2-agonist</keyword>
</DOC>